Recombinant IL-2 reduced ( p < 0.05 ) the aggravation of symptoms to 5.41.3 days , neurological deficit ( 1.60.2 EDSS scores at discharge from the hospital ) , frequency of exacerbations ( from 22.9 to 5 % ) and frequency of cases with the development of multiple sclerosis during 3 years ( from 17.1 to 2.5 % ) .